PSTV is a rare asymmetric opportunity transitioning to commercial stage with a strong focus on CNS oncology diagnostics.
Source Post
Plus Therapeutics PSTV: $65 PT Explodes July 1st! | PSTV Stock Analysis
May 6, 2026
The Investing Talk Podcast discusses Plus Therapeutics (PSTV), highlighting its transition from a clinical-stage biotech to a commercial-stage diagnostic company in the underserved CNS oncology space. Despite current net losses and grant dependency, the company is investing heavily in commercial operations and sales infrastructure, which is seen as a strategic move for future revenue growth. The podcast notes a significant drop in R&D expenses due to non-dilutive grants, indicating capital discipline.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
PSTVbuy opened May 6, 2026
-37.83%